Users can now access private company data from theJP Jenkins marketplace

Less Ads, More Data, More Tools Register for FREE
Sponsored Content
Don't want ads? Click here
Sponsored Content
Don't want ads? Click here

Pin to quick picksIQ-AI Share News (IQAI)

Share Price Information for IQ-AI (IQAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.85
Bid: 0.80
Ask: 0.90
Change: 0.00 (0.00%)
Spread: 0.10 (12.50%)
Open: 0.85
High: 0.85
Low: 0.85
Prev. Close: 0.85
IQAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Timelines are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Primorus Sells Remaining Greatland Stake

Wed, 04th Nov 2020 20:19

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Primorus Investments PLC - investment firm focused on natural resources sector - Says it has completed the sales of its remaining shareholding in Greatland Gold PLC. Primorus sold 20.0 million shares at an average price of 23.09 pence each, raising gross proceeds of around GBP4.6 million through a "structured series" of sales. As a result, the company no longer holds an interest in Greatland. "The Greatland Gold investment has, by any measure, been extremely successful. Having made a high-conviction investment call in late 2018, it has been hugely satisfying to watch Greatland grow to a market cap in excess of GBP800 million. Whilst the outlook for Greatland is extremely positive, after nearly 2 years, it is time for Primorus to realise its remaining gains and look to re-invest elsewhere in accordance with its investment mandate. Current cash reserves of Primorus now exceed the market capitalisation of the company," says Alastair Clayton, executive director of Primorus.

----------

IQ-AI Ltd - medical software company with headquarters in Jersey - Says the US Food & Drug Administration has granted 510(k) market clearance for the Liver Surface Nodularity software application. IQ-AI's subsidiary, Imaging Biometrics LLC, entered into a business agreement with the owner of LSN, AI Metrics LLC, earlier this year which granted IB global rights to manufacture, market, and distribute the LSN software platform. "Now that the FDA has granted market clearance, IB and AI Metrics will begin to actively market and sell LSN in the USA. CE mark for European distribution and commercialisation is expected later this quarter," says IQ-AI.

----------

GSTechnologies Ltd - data infrastructure, storage, and technology services firm - Wholly-owned subsidiary EMS Wiring Systems Pte Ltd has received a USD200,000 grant from Enterprise Singapore to develop a prototype liquid film cooling system for use in data centres. The entire development is valued at approximately USD1 million and will take about 12-18 months to complete.

----------

Inspirit Energy Holdings PLC - developer of combined heat and power boilers - In talks regarding a possible collaboration with an engineering company with expertise in advanced gasification. The collaboration would enable Inspirit to support the heat recovery processes within this partner's applications, it says. "In particular, Inspirit may be afforded the opportunity to participate in district heating, waste-to-energy and other energy infrastructure projects using the partner's gasification technology," says Inspirit. Will update market when the parties enter into formal collaboration.

----------

Medica Group PLC - teleradiology services provider based in Hastings, East Sussex - To buy Global Diagnostics Ireland, operating in the teleradiology reporting market in Ireland, for an initial cash consideration of EUR16 million. The deal is in line with Medica's strategy to diversify revenue sources outside of the UK, to further its market leadership position in teleradiology and expand into new areas of telemedicine. A maximum of EUR4 million deferred consideration will be paid based on contractual milestones. Adds that recent Medica trading has been in line with management expectations.

----------

Biome Technologies PLC - bioplastics and radio frequency technology - Bioplastics division starts project to develop and test a new generation of biodegradable tree shelters made from the company's bioplastics. The project has been awarded funding of GBP58,843 from the government-backed Innovate UK agency. Tree shelters are used to protect young trees and bushes from animals. This three-month project is being undertaken in conjunction with Suregreen, a tree shelter manufacturer.

----------

Mila Resources PLC - natural resources company - Though transaction to buy E-Tech Metals Ltd was "materially advanced" following due diligence and the preparation of a prospectus, E-Tech gave notice that it wished to terminate the transaction without cause. Mila has now recovered a loan of GBP87,402 advanced to E-Tech, and is receiving legal advice on the termination notice. "Mila Resources maintains a healthy cash position and is in advanced discussions with regard to other potential transactions and will update the market in due course," says Mila. Adds that trading in its shares will resume in due course following consultation with the UK Financial Conduct Authority. A further statement will be made to "clarify lifting of the suspension".

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
2 May 2025 13:28

IN BRIEF: IQ-AI applies for breakthrough therapy designation for GaM

IQ-AI Ltd - London-based medical services company - Says subsidiary Imaging Biometrics LLC has applied for breakthrough therapy designation from the US Food & Drug Administration for its oral gallium maltolate therapy. Its phase 1 trial is evaluating the therapy as a potential treatment for adult patients with recurrent or refractory glioblastoma IDH-wildtype, with preliminary findings suggesting an overall survival of 34.1 months from initial diagnosis. This significantly exceeds the median survival of 14 to 15 months reported for patients undergoing standard treatment, though IQ-AI notes that caution is appropriate when considering the results due to the size of the trial population. The FDA is required to respond to IQ-AI's application within 60 days.

Read more
3 Feb 2025 19:22

IN BRIEF: IQ-AI amends distribution deal with Blackford Analysis

IQ-AI Ltd - London-based medical services company - Amends existing distribution agreement with artificial intelligence platform provider Blackford Analysis Ltd. The amendment adds IB Nimble, IB ASL, IB FTB, and IB FTB Express to the agreement, allowing Blackford to also sell these products to their global client base. Acquired by Bayer in early 2023, Blackford operates in the healthcare AI platform and solutions sphere.

Read more
22 Jan 2025 17:10

IN BRIEF: IQ-AI to take GaM to phase II study, flags AI capabilities

IQ-AI Ltd - London-based medical services company - Provides operations update focusing on artificial intelligence. Explains radiology leads the way in Food & Drug Administration approvals for AI-enabled products as the FDA has increased efforts to keep pace with the advancements in AI technology. The company believes its subsidiary, Imaging Biometrics LLC, is in a unique position to lead this transformation for neuro-oncology in 2025 and beyond. Points to the imminent release of the new version of IB Clinic; its FDA-cleared suite of quantitative imaging solutions will include the incorporation of an AI model, which will greatly improve diagnostic accuracy and speed. In addition, notes the first half of 2025 should mark the next release of IB Nimble with the functionality to view IB's AI-generated images and other images within the mobile app. Also, in 2025 we anticipate releasing a new product leveraging arterial spin labelling.

Read more
14 Oct 2024 10:05

IN BRIEF: Braveheart buys 30% stake in IQ-AI from Braveheart CEO Brown

IQ-AI Ltd - parent of Wisconsin-based Imaging Biometrics LLC, which provides quantitative imaging platforms and therapeutics for the diagnosis and treatment of patients - AIM-listed technology investor Braveheart Investment Group PLC buys a nearly 30% stake in IQ-AI from Braveheart Chief Executive Officer Trevor Brown. Braveheart buys 45.8 million IQ-AI shares from Brown at 1.1 pence per share, worth GBP503,372, and another 19.7 million shares owned by Brown's children at the same price, worth GBP216,203. The two purchases give Braveheart a 29.5% stake in IQ-AI. Braveheart on Friday says the related-party transaction is approved by its independent shareholders because the IQ-AI business fits Braveheart's investment strategy and the purchase is at "an attractive entry price".

Read more
16 Aug 2024 20:40

TRADING UPDATES: NetScientific loss narrows; Vinanz ups Bitcoin fleet

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and Wednesday and not separately reported by Alliance News:

Read more
25 Jun 2024 11:56

IN BRIEF: IQ-AI subsidiary opens expanded access programme

IQ-AI Ltd - London-based medical services company - US-based subsidiary Imaging Biometrics LLC says that US Food & Drug Administration has approved an expanded access programme for oral gallium maltolate. This EAP will run in parallel with the current phase 1 clinical trial being conducted at the Medical College of Wisconsin. Explains that "As the phase 1 trial concludes this fall and while the data is being compiled, eligible patients in the US will have the option of participating in the EAP."

Read more
14 Jun 2024 14:32

IQ-AI team begins defining phase 2 protocol for oral gallium maltolate

(Alliance News) - IQ-AI Ltd on Friday said the clinical team has started a phase 2 protocol for its oncology-focused drug oral gallium maltolate, which could be a therapeutic agent for cancer.

Read more
23 May 2024 21:08

TRADING UPDATES: Celadon ships to US; Oxford BioDynamics-Goodbody pact

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
20 May 2024 11:16

IQ-AI subsidiary gets second FDA rare paediatric disease designation

(Alliance News) - IQ-AI Ltd on Monday said its subsidiary, Imaging Biometrics LLC, received a second rare paediatric disease designation by the US Food & Drug Administration for its IB-003 lead drug candidate oral gallium maltolate.

Read more
17 May 2024 17:39

TRADING UPDATES: Ingenta trades in line; Triple Point Social NAV up

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
10 May 2024 15:14

IQ-AI subsidiary gets rare paediatric disease designation FDA

(Alliance News) - IQ-AI Ltd on Friday said its subsidiary, Imaging Biometrics LLC, has been granted rare paediatric disease designation by the US Food & Drug Administration for its lead drug candidate, IB-003, or gallium maltolate for the treatment of ATRT.

Read more
2 May 2024 15:45

EARNINGS AND TRADING: Trident Royalties swings to profit

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
22 Feb 2024 14:02

IN BRIEF: IQ-AI shares sink on discounted placing fundraise

IQ-AI Ltd - Medical services firm and parent company of Wisconsin-based healthcare imaging software firm Imaging Biometrics LLC - Announces placing to raise GBP300,000 gross proceeds via the issue of 20.0 million new shares at a price of 1.5p each. The issue price represents a discount of 32% to the company's Wednesday closing price of 2.2p. The placing includes a broker option for existing shareholders for up to 6.7 million new shares, which would raise an additional GBP100,000. Admission of the new placing and broker option shares is expected to occur on or around March 1.

Read more
9 Feb 2024 13:38

IQ-AI subsidiary asked by FDA to resubmit and modify application

(Alliance News) - IQ-AI Ltd on Friday said its subsidiary Imaging Biometric LLC will modify and resubmit its application to the US Food & Drug Administration.

Read more
2 Feb 2024 08:56

IN BRIEF: IQ-AI celebrates USD100,000 grant for subsidiary

IQ-AI Ltd - St Helier, Jersey-based medical services firm - Says that Imaging Biometrics LLC, a wholly-owned subsidiary of IQ-AI, has been given a USD100,000 grant by the Musella Foundation For Brain Tumor Research & Information Inc. Explains that the grant will help to support the launch of an intermediate group expanded access programme, which is focused on giving brain tumour patients access to oral gallium maltolate, outside of an ongoing Phase One clinical trial at the Medical College of Wisconsin. The grant will be used to facilitate the expanded access programme, including writing and submitting the study protocol, patient screening and on-boarding.

Read more

Make Better Investment Decisions

Register for FREE

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.